Recently, a neutralizing monoclonal antibody against GPR77 was observed to effectively control tumor formation and reverse chemoresistance by eliminating CD10+ GPR77+ subpopulation of CAFs, proposing a CAF-targeted therapeutic strategy (100). Here, C5AR2 is linked to neoplasm.